L-826266 is a selective and competitive EP3 receptor antagonist. L-826266 can be used for convulsive disorders research In Vitro In adult rat hippocampal slices, L-826266 (1 μM) prevents the PGE2-induced decrease of Na+,K+-ATPase activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo L-826266 (0.01-1 nmol/site; i.c.v.; once) delays seizures, and increases the latency for clonic and generalized tonic-clonic seizures induced by PTZ . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male Wistar rats (250-300 g) injected with Pentylenetetrazol (PTZ) Dosage: 0.01 nmol/site, 0.1 nmol/site or 1 nmol/site Administration: i.c.v.; once Result: Increased the latency for clonic and generalized tonic-clonic seizures induced by PTZ. Form:Solid IC50& Target:EP3
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
L-826266
CAS number：244101-03-9 molecular formula：C27H21BrClNO4S
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | CID 9808643 | MS-30311 | SCHEMBL1061876 | (E)-N-(5-bromo-2-methoxyphenyl)sulfonyl-3-[5-chloro-2-(naphthalen-2-ylmethyl)phenyl]prop-2-enamide | L-826,266 | SCHEMBL1061880 | L-826266 | compound 10b [PMID: 11504634] | MF266-3 | Q27078442 | AKOS040748715 | LS | ||
| CAS number | 244101-03-9 | molecular formula | C27H21BrClNO4S |
| molecular weight | 570.88 g/mol | Exact mass | ≥98% |
| PSA | 80.900 Ų | logp | 7.200 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
